p53 codon 72 polymorphism and Hematological Cancer Risk: An Update Meta-Analysis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Weng, Yu ^a   Lu, Liqin ^b   Yuan, Guorong ^b   Guo, Jing ^c   Zhang, Zhizhong ^d   Xie, Xinyou ^a   Chen, Guangdi ^c   Zhang, Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; DNA POLYMORPHISM; ETHNICITY; GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENOTYPE; GEOGRAPHIC ORIGIN; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HUMAN; LEUKEMIA; LYMPHOMA; META ANALYSIS; MYELOMA; NONHODGKIN LYMPHOMA; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; AMINO ACID SUBSTITUTION; CASE CONTROL STUDY; DNA SEQUENCE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; PUBLISHING; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866705615     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045820     Document Type: Article

References (46)

1. Rodriguez-Abreu D, Bordoni A, Zucca E, (2007) Epidemiology of hematological malignancies. Ann Oncol 18Suppl 1: i3-i8.
2. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
3. Descatha A, Jenabian A, Conso F, Ameille J, (2005) Occupational exposures and haematological malignancies: overview on human recent data. Cancer Causes Control 16: 939-953.
4. Irigaray P, Newby JA, Clapp R, Hardell L, Howard V, et al. (2007) Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed Pharmacother 61: 640-658.
5. Hainaut P, Wiman KG, (2009) 30 years and a long way into p53 research. Lancet Oncol 10: 913-919.
6. Goh AM, Coffill CR, Lane DP, (2011) The role of mutant p53 in human cancer. J Pathol 223: 116-126.
7. Olivier M, Petitjean A, Marcel V, Petre A, Mounawar M, et al. (2009) Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 16: 1-12.
8. Oren M, Rotter V, (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: a001107.
9. Hrstka R, Coates PJ, Vojtesek B, (2009) Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 13: 440-453.
10. Whibley C, Pharoah PD, Hollstein M, (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
11. Francisco G, Menezes PR, Eluf-Neto J, Chammas R, (2011) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer 129: 920-930.
12. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.
13. Pim D, Banks L, (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199.
14. Siddique M, Sabapathy K, (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25: 3489-3500.
15. Chauhan PS, Ihsan R, Yadav DS, Mishra AK, Bhushan B, et al. (2011) Association of glutathione S-transferase, EPHX, and p53 codon 72 gene polymorphisms with adult acute myeloid leukemia. DNA Cell Biol 30: 39-46.
16. Havranek O, Spacek M, Hubacek P, Mocikova H, Benesova K, et al. (2011) No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma. Leuk Res 35: 1117-1119.
17. Kim HN, Yu L, Kim NY, Lee IK, Kim YK, et al. (2010) Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma. Am J Hematol 85: 822-824.
18. He XF, Su J, Zhang Y, Huang X, Liu Y, et al. (2011) Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat 130: 517-529.
19. Zhang Z, Wang M, Wu D, Tong N, Tian Y, (2010) P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 120: 509-517.
20. Feng Z, Zhang C, Kang HJ, Sun Y, Wang H, et al. (2011) Regulation of female reproduction by p53 and its family members. FASEB J 25: 2245-2255.
21. Kang HJ, Feng Z, Sun Y, Atwal G, Murphy ME, et al. (2009) Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A 106: 9761-9766.
22. Majid A, Richards T, Dusanjh P, Kennedy DB, Miall F, et al. (2011) TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol 153: 533-535.
23. Phang BH, Chua HW, Li H, Linn YC, Sabapathy K, (2011) Characterization of novel and uncharacterized p53 SNPs in the Chinese population-intron 2 SNP co-segregates with the common codon 72 polymorphism. PLoS One 6: e15320.
24. Shi H, Tan SJ, Zhong H, Hu W, Levine A, et al. (2009) Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet 84: 534-541.
25. Sturm I, Bosanquet AG, Hummel M, Dorken B, Daniel PT, (2005) In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 5: 105.
26. Yamaguchi H, Inokuchi K, Sakuma Y, Dan K, (2001) Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 15: 1729-1734.
27. Hu W, Feng Z, Atwal GS, Levine AJ, (2008) p53: a new player in reproduction. Cell Cycle 7: 848-852.
28. Ito A, Morita A, Ohya S, Yamamoto S, Enomoto A, et al. (2011) Cycloheximide suppresses radiation-induced apoptosis in MOLT-4 cells with Arg72 variant of p53 through translational inhibition of p53 accumulation. J Radiat Res (Tokyo) 52: 342-350.
29. Miwa H, Kita K, Saya H, Otsuji A, Masuya M, et al. (1992) Structural alterations of the p53 gene in human leukemias. Leuk Res 16: 1105-1112.
30. Zhang W, Hu G, Deisseroth A, (1992) Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 117: 271-275.
31. Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT, (2009) TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet 195: 31-36.
32. Bittenbring J, Parisot F, Wabo A, Mueller M, Kerschenmeyer L, et al. (2008) MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians. BMC Cancer 8: 116.
33. Hill DA, Wang SS, Cerhan JR, Davis S, Cozen W, et al. (2006) Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 108: 3161-3167.
34. Hishida A, Matsuo K, Tajima K, Ogura M, Kagami Y, et al. (2004) Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk Lymphoma 45: 957-964.
35. Ortega MM, Honma HN, Zambon L, Lorand-Metze I, Costa FF, et al. (2007) GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Ann Hematol 86: 815-819.
36. Pospelova TI, Voropaeva EN, Voevoda MI, Berezina1 OV (2010) p53 polymorphisms as a potential marker for predisposition for non-Hodgkin malignant lymphomas. Haematology and Transfusiology 1.
37. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, et al. (2004) TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 89: 868-869.
38. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, et al. (2008) MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 112: 741-749.
39. Kochethu G, Delgado J, Pepper C, Starczynski J, Hooper L, et al. (2006) Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 30: 1113-1118.
40. Nakano Y, Naoe T, Kiyoi H, Kunishima S, Minami S, et al. (2000) Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. Leuk Res 24: 349-352.
41. Phang BH, Linn YC, Li H, Sabapathy K, (2008) MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer 44: 760-766.
42. Takeuchi S, Matsushita M, Tsukasaki K, Takeuchi N, Tomonaga M, et al. (2005) P53 codon 72 polymorphism is associated with disease progression in adult T-cell leukaemia/lymphoma. Br J Haematol 131: 552-553.
43. Xiong X, Wang M, Wang L, Liu J, Zhao X, et al. (2009) Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 33: 1454-1458.
44. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I, (2006) The case of the misleading funnel plot. BMJ 333: 597-600.
45. Zintzaras E, Lau J, (2008) Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61: 634-645.
46. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61: 991-996.